Victoza: Advanced GLP-1 Therapy for Type 2 Diabetes Management
| Product dosage: 6mg | |||
|---|---|---|---|
| Package (num) | Per injector | Price | Buy |
| 1 | $452.85 | $452.85 (0%) | 🛒 Add to cart |
| 2 | $427.69
Best per injector | $905.69 $855.37 (6%) | 🛒 Add to cart |
Synonyms | |||
Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is administered via subcutaneous injection and functions by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying. Clinical trials have demonstrated its efficacy in reducing HbA1c levels, supporting weight management, and offering cardiovascular benefits for certain patient populations. Victoza represents a significant therapeutic option for individuals requiring advanced pharmacological intervention beyond first-line oral antidiabetic agents.
Features
- Active ingredient: liraglutide 6 mg/mL
- Delivery: pre-filled, multi-dose pen injector
- Dosing: adjustable (0.6 mg, 1.2 mg, or 1.8 mg daily)
- Storage: refrigerated at 2°C to 8°C (36°F to 46°F); may be kept at room temperature (below 30°C/86°F) for up to 30 days
- Needle: 32G, 6mm (included separately)
- Prescription-only medication
Benefits
- Significantly lowers HbA1c levels through glucose-dependent mechanisms
- Promotes weight loss by reducing appetite and slowing gastric emptying
- Demonstrates cardiovascular risk reduction in patients with established cardiovascular disease
- Low risk of hypoglycemia when used without sulfonylureas or insulin
- Once-daily dosing supports adherence and convenience
- May preserve beta-cell function over time
Common use
Victoza is primarily prescribed for adults with type 2 diabetes mellitus whose glycemic control remains inadequate despite lifestyle modifications and/or other antidiabetic medications. It is often used in combination with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when additional glycemic control is needed. It may also be considered for patients who would benefit from weight management or have comorbid cardiovascular disease.
Dosage and direction
Initiate treatment with 0.6 mg subcutaneously once daily for at least one week to reduce gastrointestinal symptoms. Increase to 1.2 mg daily. If additional glycemic control is required, the dose may be increased to 1.8 mg after at least one week on the 1.2 mg dose. Administer at any time of day, independently of meals. Inject subcutaneously in the abdomen, thigh, or upper arm; rotate injection sites to prevent lipodystrophy. Prime the pen before first use.
Precautions
- Not recommended as first-line therapy for patients inadequately controlled with diet and exercise alone
- Use with caution in patients with renal impairment (not recommended if eGFR <30 mL/min)
- Monitor for signs and symptoms of pancreatitis; discontinue if suspected
- May cause dehydration; advise adequate fluid intake
- Not recommended in patients with severe hepatic impairment
- Thyroid C-cell tumors observed in rodents; relevance to humans unknown
- Instruct patients on proper injection technique and needle disposal
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of hypersensitivity to liraglutide or any product components
- Should not be used in patients with type 1 diabetes or for treatment of diabetic ketoacidosis
Possible side effects
Common (≥5%):
- Nausea
- Diarrhea
- Headache
- Vomiting
- Constipation
Less common:
- Dyspepsia
- Decreased appetite
- Fatigue
- Dizziness
- Abdominal pain
- Injection site reactions
Serious (report immediately):
- Pancreatitis (severe abdominal pain radiating to the back)
- Allergic reactions (rash, itching, difficulty breathing)
- Acute kidney injury
- Gallbladder disease
- Increased heart rate
Drug interaction
- May enhance the hypoglycemic effect of insulin and insulin secretagogues (e.g., sulfonylureas); dose reduction of these agents may be necessary
- May delay gastric emptying, potentially affecting absorption of orally administered drugs (e.g., antibiotics, oral contraceptives)
- Use with caution with drugs that slow intestinal transit (e.g., anticholinergics)
- No clinically significant interaction with warfarin observed
Missed dose
If a dose is missed, it should be administered as soon as possible on the same day. Do not administer two doses on the same day. Resume the regular dosing schedule the following day.
Overdose
Effects may include severe nausea, vomiting, and hypoglycemia. In clinical trials, doses up to 10 times the maximum recommended dose resulted in gastrointestinal disturbances. No specific antidote exists; provide supportive treatment and symptomatic management. Hypoglycemia should be treated with oral carbohydrates or intravenous glucose as appropriate.
Storage
Store unused pens refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. After first use, store at room temperature below 30°C (86°F) or refrigerate; discard after 30 days. Keep pen cap on when not in use. Do not store with needle attached. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual patient needs may vary. Always consult with a qualified healthcare professional before starting, changing, or stopping any medication. The prescriber should be familiar with the complete prescribing information and approved indications.
Reviews
Clinical studies and real-world evidence consistently demonstrate Victoza’s efficacy in glycemic control and weight management. The LEAD (Liraglutide Effect and Action in Diabetes) trial program showed HbA1c reductions of 1.0% to 1.5% and weight loss of 2-3 kg. The landmark LEADER trial demonstrated a 13% reduction in major adverse cardiovascular events in high-risk patients. Many clinicians report improved patient satisfaction due to once-daily dosing and weight loss benefits. Some patients note initial gastrointestinal side effects that typically diminish over several weeks. Overall, Victoza remains a well-established option in the type 2 diabetes treatment algorithm.